Cytoplasmic retention of IRF3 binding Vimentin competitively with ERK1/2 mitigates acute myeloid leukemia through TFEB nuclear translocation
A molecular pathway in leukemia cells offers a potential new drug target, though human studies are still needed.
This preclinical mechanistic study identifies an IRF3-Vimentin-ERK1/2-TFEB molecular axis in AML that may serve as a therapeutic target; the cytoplasmic retention of IRF3 via competitive Vimentin binding is described as a driver of AML pathogenesis. No clinical validation data; exploratory preclinical stage.
What the study was
- Study design
- Preclinical mechanistic study
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Cell Communication and Signaling
Why it surfaced
Preclinical mechanistic AML study; capped at 5 for non-human/mixed model per scoring rules; no abstract text available for full scoring.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.